Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9NPI8
UPID:
FANCF_HUMAN
Alternative names:
-
Alternative UPACC:
Q9NPI8; Q52LM0
Background:
The Fanconi anemia group F protein plays a crucial role in DNA repair, particularly in postreplication repair or cell cycle checkpoint functions. It is instrumental in interstrand DNA cross-link repair and maintaining chromosome stability, which is vital for the integrity of genetic information.
Therapeutic significance:
Fanconi anemia complementation group F, a disorder linked to this protein, affects bone marrow elements leading to various malformations and a predisposition to malignancies. Understanding the role of Fanconi anemia group F protein could open doors to potential therapeutic strategies for this complex condition.